Securities code: Jiangsu Chinagreen Biological Technology Co.Ltd(300970) securities abbreviation: Jiangsu Chinagreen Biological Technology Co.Ltd(300970) Announcement No.: 2022016 Jiangsu Chinagreen Biological Technology Co.Ltd(300970)
Announcement on applying for comprehensive credit line from financial institutions in 2022
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Jiangsu Chinagreen Biological Technology Co.Ltd(300970) (hereinafter referred to as “the company”) held the 12th meeting of the 4th board of directors and the 12th meeting of the 4th board of supervisors on April 8, 2022, and deliberated and adopted the proposal on applying for comprehensive credit line from financial institutions in 2022, which needs to be submitted to the 2021 annual general meeting of shareholders of the company for deliberation. The details are hereby announced as follows:
1、 Overview of applying for comprehensive credit line
In order to meet the daily operating funds and business development needs of the company (including wholly-owned subsidiaries and holding subsidiaries) in 2022, and actively expand capital channels, the company plans to apply to financial institutions for comprehensive credit with a total line of no more than RMB 400 million (including this amount, which is finally subject to the comprehensive credit line actually approved by financial institutions) in 2022. The purpose of comprehensive credit application includes but is not limited to loan, acceptance bill, letter of guarantee, factoring, bill discount and other businesses. The credit line is not equal to the actual financing amount of the company. The actual financing amount within the credit line shall be subject to the actual financing amount between the financial institution and the company. Within the credit term, the credit line can be recycled.
At the same time, the chairman of the company is authorized to sign all credit documents within the above credit line on behalf of the company, and all the legal and economic responsibilities arising therefrom shall be borne by the company. The above credit authorization period is from the date of deliberation and approval of the 2021 annual general meeting of shareholders to the date of convening the next annual general meeting of shareholders.
2、 Approval decision procedure
1. Deliberation of the board of directors
On April 8, 2022, the company held the 12th meeting of the 4th board of directors, deliberated and approved the proposal on applying for comprehensive credit line from financial institutions in 2022, and all directors unanimously agreed that the company applied for comprehensive credit line from financial institutions in 2022 (the final comprehensive credit line approved by financial institutions shall prevail). The proposal still needs to be submitted to the 2021 annual general meeting of shareholders for deliberation.
2. Deliberation of the board of supervisors
The company held the 12th meeting of the 4th board of supervisors on April 8, 2022, deliberated and adopted the proposal on applying for comprehensive credit line from financial institutions in 2022, and all supervisors unanimously agreed that the company applied for comprehensive credit line from financial institutions in 2022. The proposal still needs to be submitted to the general meeting of shareholders for deliberation.
3. Opinions of independent directors
After verification, the independent directors believe that the company’s application for comprehensive credit line is to meet the actual capital needs of the company’s daily operation, help stabilize the company’s sustainable development and accelerate the national strategic layout, and play a positive role in the company’s production and operation. The proceeding of this matter does not harm the interests of the company and all shareholders. The independent directors unanimously agreed that the company would apply for a comprehensive credit line from financial institutions in 2022 and agreed to submit this proposal to the general meeting of shareholders for deliberation. 3、 Documents for future reference
1. Resolutions of the 12th meeting of the 4th board of directors;
2. Resolutions of the 12th meeting of the 4th board of supervisors;
3. Independent opinions of independent directors on matters related to the 12th meeting of the Fourth Board of directors of the company. It is hereby announced.
Jiangsu Chinagreen Biological Technology Co.Ltd(300970) board of directors April 8, 2022
